Biohaven Price to Sales Ratio 2016-2022 | BHVN

Historical PS ratio values for Biohaven (BHVN) over the last 10 years. The current P/S ratio for Biohaven as of February 03, 2023 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Biohaven P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2023-02-03 18.19 1.44
2022-09-30 151.17 $12.60 12.00
2022-06-30 145.71 $12.60 11.57
2022-03-31 118.57 $11.00 10.78
2021-12-31 137.81 $7.17 19.22
2021-09-30 138.91 $2.73 50.85
2021-06-30 97.08 $3.03 32.07
2021-03-31 68.35 $1.77 38.72
2020-12-31 85.71 $1.08 79.41
2020-09-30 65.01 $0.48 135.02
2020-06-30 73.11 $0.19 394.13
2020-03-31 34.03 $0.02 1667.85
2019-12-31 54.44 0 0.00
2019-09-30 41.72 0 0.00
2019-06-30 43.79 0 0.00
2018-12-31 36.98 0 0.00
2018-09-30 37.55 0 0.00
2018-06-30 39.52 0 0.00
2018-03-31 25.76 0 0.00
2017-12-31 26.98 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.307B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.721B 9.45
GSK (GSK) United Kingdom $71.915B 9.49
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.215B 19.14
Ginkgo Bioworks Holdings (DNA) United States $4.249B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.532B 23.00
Emergent Biosolutions (EBS) United States $0.726B 5.71
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Ambrx Biopharma (AMAM) United States $0.071B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00